Dies ist eine Übersichtsseite mit Metadaten zu dieser wissenschaftlichen Arbeit. Der vollständige Artikel ist beim Verlag verfügbar.
Industrializing AI-powered drug discovery: lessons learned from the <i>Patrimony</i> computing platform
19
Zitationen
14
Autoren
2022
Jahr
Abstract
INTRODUCTION: was built up on the initial predicate to capitalize on our proprietary data while leveraging public data sources in order to foster a Computational Precision Medicine approach with the power of artificial intelligence. AREAS COVERED: is designed to identify novel therapeutic target candidates. With several successful use cases in immuno-inflammatory diseases, and current ongoing extension to applications to oncology and neurology, we document how this industrial computational platform has had a transformational impact on our R&D, making it more competitive, as well time and cost effective through a model-based educated selection of therapeutic targets and drug candidates. EXPERT OPINION: We report our achievements, but also our challenges in implementing data access and governance processes, building up hardware and user interfaces, and acculturing scientists to use predictive models to inform decisions.
Ähnliche Arbeiten
Explainable Artificial Intelligence (XAI): Concepts, taxonomies, opportunities and challenges toward responsible AI
2019 · 8.611 Zit.
Stop explaining black box machine learning models for high stakes decisions and use interpretable models instead
2019 · 8.504 Zit.
High-performance medicine: the convergence of human and artificial intelligence
2018 · 8.025 Zit.
BioBERT: a pre-trained biomedical language representation model for biomedical text mining
2019 · 6.835 Zit.
Proceedings of the 19th International Joint Conference on Artificial Intelligence
2005 · 5.781 Zit.